Provided by Tiger Trade Technology Pte. Ltd.

Neoleukin Therapeutics, Inc.

3.49
0.0000
Volume:- -
Turnover:393.37K
Market Cap:32.80M
PE:-1.14
High:3.49
Open:3.49
Low:3.49
Close:3.49
52wk High:4.70
52wk Low:1.90
Shares:9.40M
Float Shares:5.45M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.0649
EPS(LYR):-5.2115
ROE:-37.88%
ROA:-18.70%
PB:0.44
PE(LYR):-0.67

Loading ...

Company Profile

Company Name:
Neoleukin Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.